Tagged With "Eczema Awareness Month"

Blog Post

A High Number of Adults Manage Atopic Dermatitis

AAFA Community Services ·
Atopic dermatitis (AD) is a chronic condition where your skin becomes dry and itchy too easily. This can lead to allergies and inflammation. It is more common in children than adults. But current research suggests that more adults may have it than once thought. AD is also sometimes called eczema. There is no cure.
Blog Post

AAFA Study Highlights Negative Impact Eczema Can Have on Quality of Life

AAFA Community Services ·
If you’ve never suffered from eczema, also known as atopic dermatitis, you probably aren’t aware of the negative impact it can have on quality of life. The severe itching, redness and excessively dry skin all make life miserable for those who suffer from the allergic disease.
Blog Post

Atopic Dermatitis in America: Find Relief for This Painful Itchy Rash

AAFA Community Services ·
If you have atopic dermatitis (AD) , you know a dry, itchy, red rash on your hands, arms, legs or other parts of the body is a part of daily life. AD is an allergic condition and the most common type of eczema. More than 18 million Americans of all ages have AD. The severity of AD can be different for each person and does not depend on when you developed the disease. However, AAFA’s recent study titled Atopic Dermatitis in America found that people with adult- and late childhood-onset AD...
Blog Post

Ask the Allergist: Does Eczema Affect Allergy Testing?

AAFA Community Services ·
I have eczema and seasonal allergies. My doctor wants to do a skin test to see if I should get allergy shots. Can I get allergy shots if I have eczema? Does eczema affect the accuracy of allergy skin test results?
Blog Post

Case Study Shows Allergy Shots May Improve Severe Eczema

AAFA Community Services ·
If you’ve suffered with severe atopic dermatitis (eczema) for a long time and have tried what you think is every available option for relief, you may want to consider allergy shots. A medically-challenging case being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting found that allergy shots provided significant benefits to the eczema symptoms suffered by a 48-year-old man.
Blog Post

Dupixent® Shows Positive Results in Phase 3 of Trial for Ages 6 to 11 With Severe Atopic Dermatitis

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.
×
×
×
×